SCHEMBL6456244

SCHEMBL6456244

CC(C)(c1ccccc1)c1ccc(-c2ccc(C(C)(C)c3ccccc3)cc2)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 4/20 0.65
ESR2 Q92731 4/20 0.65
CYP3A4 P08684 2/20 0.65
ALDH1A1 P00352 2/20 0.65
NR3C2 P08235 3/20 0.50
KIF11 P52732 1/20 0.50
AR P10275 1/20 0.48
HPGD P15428 1/20 0.48
TSHR P16473 1/20 0.48
SLC6A2 P23975 1/20 0.48
SLC6A4 P31645 1/20 0.48
HTR6 P50406 1/20 0.48
ESRRG P62508 1/20 0.48
SLC6A3 Q01959 1/20 0.48
HSD17B10 Q99714 1/20 0.48
CNR1 P21554 4/20 0.47
CNR2 P34972 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
MAPK1 P28482 1/20 0.46
KMT2A Q03164 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18913698 0.97 ESR1 (0.62) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL15832876 0.94 ALDH1A1 (0.58) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL7535051 0.91 ESR1 (0.75) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL26411210 0.89 CYP1A2 (0.58) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL16505951 0.89 ESR1 (0.87) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL14910456 0.88 ESR1 (0.70) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL35881 0.88 ESR1 (0.70) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL18801808 0.87 KIF11 (0.53) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL16592828 0.87 ESR1 (0.52) ESR1ESR2CYP3A4ALDH1A1NR3C2
SCHEMBL13700827 0.87 ESR1 (0.52) ESR1ESR2CYP3A4ALDH1A1NR3C2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3919533-B1 RADICAL-CURABLE SEAL MEMBER FOR FUEL CELL SUMITOMO RIKO CO LTD (JP) 2023-07-12 EP disclosed
US-20050159519-A1 Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent NOK CORPORATION 2005-07-21 US disclosed
US-6329551-B1 HIGH TEMPERATURE STABILITY NOK CORPORATION (JP) 2001-12-11 US disclosed
US-6093853-A N,N'-(MONO,DI, OR TRI-((ALKOXY)(SUBSTITUTED)PHENYLALKYL) PHENYL) PHENYLENEDIAMINE; MADE BY REACTING N,N'-DIPHENYL-1,4-PHENYLENEDIAMINE AND A STYRENE DERIVATIVE OF GIVEN FORMULA IN THE PRESENCE OF A PROTONIC ACID CATALYST NOK CORPORATION (JP) 2000-07-25 US disclosed
EP-0395183-B1 Polyketone polymer compositions SHELL INT RESEARCH (NL) 1994-07-13 EP disclosed
US-4007230-A A PHENOL AND 4,4'-BIS(ALPHA,ALPHA-DIMETHYLBENZYL)DIPHENYLAMINE THE DOW CHEMICAL COMPANY (US) 1977-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050159519-A1 Phenylenediamine derivative, production method thereof and antioxidant for rubber using it as effective constituent PNMT, PRMT1, DNMT1 ESR1 2335/4885ESR2 655/4885CYP3A4 515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.